Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP1274 | DOI: 10.1530/endoabs.49.EP1274

1Holycross Cancer Centre, Kielce, Poland; 2The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland.


Introduction: Selenium (Se) deficiency is a known risk factor for autoimmune thyroid diseases including Graves’ orbitopathy (GO).

Objective: To determine the concentration of Se in serum and to determine the dependency of Se concentration on known markers of disease severity: the TRAB levels and the CAS (clinical activity score) in patients with GO.

Material: 64 patients (50 women, 14 men; average age- 54.5 years) with active, moderate to severe GO who have not received prior selenium supplementation and were qualified to i.v. metylprednisolone treatment according to the EUGOGO scheme, at a single site in the years 2014–2016.

Method: Set average and median concentrations of Se, TRAB and CAS in the group of patients and determined the correlation coefficients between serum Se and TRAB and CAS.

Results: Selenium deficiency was found in 15 patients, in 27 the concentration was normal, in 22- the Se level was above the upper limit of normal. There was no correlation between Se and CAS or TRAB revealed.

Conclusions: 1) The severity of OG expressed by well known indicators: CAS and TRAB were not dependent on the concentration of Se. 2) It seems that it should be recommended to measure the concentration of selenium before starting the supplementation of Se because of low frequency of Se deficiency in this group of patients.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.